CMV-specific T-cell therapy (University of Wisconsin-Madison)

N/A

Report date: 2024/11/02 20:00:07

Base Information

Drug NameCMV-specific T-cell therapy (University of Wisconsin-Madison)
Drug Alias NameCytomegalovirus-specific T-cell therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsViremiaCytomegalovirus InfectionsOpportunistic Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Wisconsin-Madison
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Wisconsin-Madison
Active IndicationsN/A
Inactive IndicationsViremiaCytomegalovirus InfectionsOpportunistic Infections

Other Information

ATC CodeN/A
Related LinksN/A